NGeneBio announced Monday that it has added a new feature to its next-generation sequencing (NGS) technology-based cancer gene analysis software, NGeneAnalySys. The new feature provides a reporting system that identifies biomarkers for specific therapeutics and immunotherapies.

NGeneBio successfully launched NGeneAnalySys in 2016 by combining its big data technology with bioinformatics.

NGeneAnalySys differentiates itself by automatically analyzing cancer genomic data and recommending treatments according to patient characteristics.

NGeneAnalySys is supplied to more than 20 hospitals in Korea, as well as to clients in the Middle East, Singapore, and Europe.

"By identifying diagnostic biomarkers for over 40 targeted anticancer drugs, clinicians can pinpoint the specific cancer-causing genetic variants and prescribe appropriate therapies.

The company said the companion diagnostics market is expected to grow by 15.5 percent annually from $5.55 billion in 2022 to $11.44 billion in 2027, especially in oncology where companion diagnostics is most active, citing data from BCC Research. 

"NGeneAnalySys's new feature can strengthen business cooperation with global pharmaceutical companies developing cancer-targeted therapies. With this upgraded feature, we expect to generate additional stable revenue," said NGeneBio CEO Choi Dae-chul.